MORGAN STANLEY - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 41 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.

Quarter-by-quarter ownership
MORGAN STANLEY ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2023$6,115
-89.7%
30,555
+5.6%
0.00%
Q2 2023$59,612
-53.5%
28,938
-25.5%
0.00%
Q1 2023$128,139
+224.3%
38,830
+61.1%
0.00%
Q4 2022$39,518
-75.6%
24,096
-34.0%
0.00%
Q3 2022$162,000
+43.4%
36,517
-10.9%
0.00%
Q2 2022$113,000
-31.1%
40,982
-16.5%
0.00%
Q1 2022$164,000
-20.8%
49,106
-4.9%
0.00%
Q4 2021$207,000
+19.0%
51,660
-1.6%
0.00%
Q3 2021$174,000
-15.1%
52,514
-2.2%
0.00%
Q2 2021$205,000
+41.4%
53,685
+42.3%
0.00%
Q1 2021$145,000
-85.0%
37,721
-82.3%
0.00%
Q4 2020$964,000
-47.1%
213,002
+97.9%
0.00%
Q3 2020$1,821,000
+92.9%
107,652
+27.8%
0.00%
Q2 2020$944,000
+686.7%
84,239
+226.1%
0.00%
Q1 2020$120,000
+46.3%
25,832
+34.1%
0.00%
Q4 2019$82,000
+15.5%
19,265
+5.8%
0.00%
Q3 2019$71,000
-13.4%
18,211
-12.3%
0.00%
Q2 2019$82,000
-5.7%
20,764
+3.8%
0.00%
Q1 2019$87,000
+148.6%
19,995
+104.1%
0.00%
Q4 2018$35,000
-5.4%
9,7950.0%0.00%
Q3 2018$37,000
-82.1%
9,795
-81.5%
0.00%
Q2 2018$207,000
+33.5%
53,077
+7.9%
0.00%
Q1 2018$155,000
+384.4%
49,200
+500.0%
0.00%
Q4 2017$32,000
+28.0%
8,200
+36.7%
0.00%
Q3 2017$25,0000.0%6,0000.0%0.00%
Q2 2017$25,000
-51.9%
6,000
-50.0%
0.00%
Q1 2017$52,000
+188.9%
12,000
+71.4%
0.00%
Q4 2016$18,000
+800.0%
7,000
+600.0%
0.00%
Q3 2016$2,0001,000
+900.0%
0.00%
Q3 2015$01000.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q1 2022
NameSharesValueWeighting ↓
Weaver Consulting Group 130,000$437,0000.21%
Ikarian Capital, LLC 304,161$1,022,0000.13%
ABNER HERRMAN & BROCK LLC 265,000$890,0000.12%
S.C. Financial Services, Inc. 15,285$51,0000.06%
JMAC ENTERPRISES LLC 45,430$153,0000.04%
CFO4Life Group, LLC 12,000$40,0000.01%
OSAIC HOLDINGS, INC. 10,839$1,329,0000.00%
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC 3,000$10,0000.00%
BOOTHBAY FUND MANAGEMENT, LLC 29,186$98,0000.00%
RAYMOND JAMES & ASSOCIATES 190,403$640,0000.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders